期刊
FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.1105779
关键词
chronic lymphocytic leukemia (CLL); allogeneic hematopoietic cell transplant; graft-versus-hose disease (GvHD); Conditioning; graft-versus-leukemia (GvL)
类别
Although the use of allogeneic HCT for CLL has declined, it remains important for high-risk or heavily pretreated patients. The procedure carries risks of GVHD, infection, and NRM, but advancements have made it safer and more effective. This review focuses on evidence-based strategies to maximize benefit and minimize toxicity of allogeneic HCT for CLL.
Although the use of allogeneic hematopoietic cell transplantation (HCT) for chronic lymphocytic leukemia (CLL) has declined with the development of novel targeted agents, it continues to play an important role for eligible patients with high-risk or heavily pretreated CLL who lack other treatment options. CLL is susceptible to a potent graft-versus-leukemia (GVL) effect which produces long-lasting remissions in 30-50% of transplanted patients. While allogeneic HCT is associated with significant risks of graft-versus-host disease (GVHD), infection, and non-relapse mortality (NRM), improvements in patient and donor selection, reduced intensity conditioning (RIC), GVHD prophylaxis, and supportive care have rendered this an increasingly safe and effective procedure in the current era. In this review, we discuss recent advances in allogeneic HCT for CLL, with a focus on the optimal evidence-based strategies to maximize benefit and minimize toxicity of this potentially curative cellular therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据